Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.
Liuting Zeng, Kailin Yang, Yang Wu...
https://pubmed.ncbi.nlm.nih.gov/39146891Actively Recruiting
Age: 18Years - 85Years
All Genders
ID07491016
A Study on the Clinical Efficacy and Safety of Telitacicept Combined With Baricitinib in the Treatment of Difficult-to-Treat Rheumatoid Arthritis (D2T RA)
Led by Zhejiang Provincial People's Hospital · Updated on 2026-03-30
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the clinical effectiveness and safety of combining telitacicept with baricitinib for patients with difficult-to-treat rheumatoid arthritis (D2T RA). It focuses on patients who have not responded adequately to traditional and multiple biological or targeted disease-modifying anti-rheumatic drugs. The study is observational and sponsored by Zhejiang Provincial People's Hospital. Participants will receive a combined treatment of telitacicept and baricitinib. This single group treatment approach involves monitoring patients who require this combination due to the ineffectiveness of previous therapies. The study will carefully observe the treatment's effects and any adverse events over a period of up to one year. During the study, participants will be regularly assessed for treatment response and safety outcomes. Researchers will track clinical efficacy measures and record any treatment-emergent adverse events. The study will last up to one year, during which patients' adherence to the prescribed treatment regimen and overall health will be monitored to ensure comprehensive evaluation of the combined therapy.
CONDITIONS
Brief Title
Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
Who Can Participate
Age: 18Years - 85Years
All Genders
Eligibility Criteria
You may qualify if you...
- Age 18 to 85 years
- Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR diagnostic criteria
- Ineffective response to traditional disease-modifying anti-rheumatic drugs and two or more biological/targeted treatments
- Voluntarily provided written informed consent
You will not qualify if you...
- Severe diseases of major organs such as heart, liver, or lungs
- Malignancies, blood disorders, or other autoimmune diseases except rheumatoid arthritis
- History of allergy or hypersensitivity to telitacicept or tofacitinib
- Active tuberculosis or infectious diseases needing systemic treatment
- Pregnancy, breastfeeding, or refusal to use contraception during the study
- Incomplete prescribed telitacicept plus tofacitinib treatment due to non-adherence or severe adverse reactions
- Other conditions that contraindicate participation as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 1 year
Participants who receive Telitacicept combined with Baricitinib are observed to assess the treatment's efficacy and safety.
Regular visits during treatment as per clinical protocol
Trial Site Locations
Total: 1 location
1
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Loading map...
Research Team
Z
Zhenhua Ying
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here